The observed effects—induction of a rich and diverse TCR repertoire together with the expression of transcription factors representative for central memory T cells—are in line with the previous reports demonstrating a positive impact of BRAF/MEK inhibitors on the outcome of immunotherapy of melanoma [8, 25], as well as in other cancers [16]. The gene discussed is MAP2K7; the disease is melanoma.